overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic
clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: email@example.com
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.